



CATÓLICA
FACULDADE DE MEDICINA DENTÁRIA

VISEU

MORFOLOGIA DA BASE DO CRÂNIO EM INDIVÍDUOS COM SÍNDROME DE APERT

Dissertação apresentada à Universidade Católica Portuguesa
para obtenção do grau de Mestre em Medicina Dentária

Por:
Aline Cássia Inocêncio

Viseu, 2020



CATÓLICA
FACULDADE DE MEDICINA DENTÁRIA

VISEU

MORFOLOGIA DA BASE DO CRÂNIO EM INDIVÍDUOS COM SÍNDROME DE APERT

Dissertação apresentada à Universidade Católica Portuguesa
para obtenção do grau de Mestre em Medicina Dentária

Por:
Aline Cássia Inocêncio

Orientador: Susana Silva
Coorientador: Ana Lúcia Ciamponi

Viseu, 2020

Epígrafe

“Quanto mais aumenta nosso conhecimento,
mais evidente fica nossa ignorância”. (John F. Kennedy)

Dedicatória

Dedico esse trabalho ao meu amado esposo André que sempre me apoiou
na realização dos meus sonhos.

Agradecimentos

Aos doentes portadores de Síndrome de Apert , agradeço à disposição em contribuir com esse estudo que visa aprimorar o tratamento ortodôntico cirúrgico e com isso almejamos oferecer melhor qualidade de vida . Sem a participação de vocês esse estudo não seria possível . Deixo aqui registado o meu MUITO OBRIGADA!

Agradeço a minha orientadora Susana Silva pela colaboração nesse estudo .

Agradeço a minha co- orientadora Ana Lúcia Ciamponi pelos ensinamentos e que me fez adquirir o interesse pela odontopediatria . Que sua voluntariedade em ajudar no tratamento dentário das crianças com necessidades especiais continue e que você brilhe mais e mais .

À Universidade Católica Portuguesa meu muito obrigada por tornar esse sonho possível .

À Universidade de São Paulo e Universidade Paulista Júlio de Mesquita Filho agradeço imensamente pela minha formação profissional.

Ao Hospital SOBRAPAR agradeço a colaboração na convocação dos doentes para que esse estudo pudesse ser realizado.

Agradeço a minha amiga e binômia Helena Romanos por poder compartilhar o dia- dia da clínica comigo. Desejo muito sucesso na sua carreira profissional que a sua luz brilhe cada vez mais.

Agradeço aos meus colegas de curso Alcion, Alessandro , Alexandre, Cibele, Erica, Erika, Fábio, Joanna, Luiz, Rafael, Thomas, Tobias , Vanesa, Júlia, João Carlos , Reinaldo e Rodrigo por fazerem essa jornada mais leve e mais divertida . Espero que possamos manter contato e desejo muito sucesso na carreira profissional de cada um de vocês , seja onde estiverem.

Resumo

A Síndrome de Apert é caracterizada por craniossinostoses e sindactilia dos dedos das mãos e dos pés. Os genes mais frequentemente mutados nas craniossinostoses síndrômicas são FGFRs que causam alteração nas células de fibroblastos e aumenta a taxa de diferenciação óssea. Essas malformações causam diminuição do crescimento da base do crânio com hipoplasia da face associada a severa retrusão maxilar. O tratamento inclui vários procedimentos cirúrgicos que são adaptados às necessidades do indivíduo afetado. O objetivo desse estudo foi avaliar comprimento, a largura e a rotação da base do crânio de maneira a verificar se estas teriam influência sobre a disposição das estruturas esqueléticas faciais.

Materiais e Métodos: Foram analisadas imagens obtidas de Tomografia Computadorizada Feixe Cônico e as grandezas cefalométricas angulares e lineares foram mensuradas pelo Software Dolphin (USA). A amostra foi composta por 22 indivíduos que foram divididos em 2 grupos: O Grupo 1 foi composto por 11 indivíduos com Síndrome de Apert com idade média de 15,6 anos e o grupo 2 foi composto por 11 indivíduos não síndrômicos pareados por sexo e idade com perfil facial equilibrado e em classe I.

Resultados: Foram calculados coeficiente de correlação intraclases para verificar reprodutibilidade e confiabilidade das medidas. A comparação entre os grupos G1 e G2 foram realizadas pelo teste t student e mostrou diferença significativa nas grandezas N.S.Ba ($p = 0.006$), Fcrant ant dir- Fcrant ante esq ($p = < 0.0001$), F crant med dir - Fcrant med esq ($p = 0,0001$), S-N / largura da fossa craniana anterior ($p = 0.0420$), S-Ba / largura fossa craniana média ($p = 0.0087$). Não houve diferenças significativas nas medidas N-S e N- Ba.

Conclusão: A base craniana dos indivíduos com síndrome de Apert possui alterações morfológicas importantes. O crânio é mais largo e curto e a maxila possui rotação mais vertical que favorece um posicionamento mais retruído influenciando o tipo de mal oclusão CIII.

Palavras chave: Apert, Síndrome de Apert, Craniossinostoses, Acrocefalodactilia

Abstract

Objective: The aim of this study was to evaluate the length, width and rotation of the base of the skull in order to verify whether these factors influence the disposition of skeletal structures.

Settings and Sample Population: The sample consisted of 22 individuals who were divided into two groups: AS group, composed of 11 individuals with Apert Syndrome (mean age of 15.6 years), and a control group.

Materials and Method: Images obtained from cone beam computed tomography were analysed and angular and linear cephalometric measurements were measured using Dolphin Software (USA). A comparison between groups was performed via T Student's.

Results: The morphology of the skull base of individuals with Apert syndrome is different to that of the normal population and it showed a significant difference in magnitudes for N.S.Ba ($p = 0.0062$), Fcrant ant right- Fcrant ant left ($p \leq 0.0001$), F crant med right- Fcrant med left ($p = 0,0001$) , S-N / width cranial anterior fossa ($p = 0.0420$) and S-Ba / width cranial median fossa ($p = 0.0087$).

Conclusion: The cranial base of the individuals with Apert Syndrome underwent important morphological alterations. The skull was wider and shorter, and the maxilla had a more vertical rotation that favoured a more retruded position which influences the type of malocclusion.

Índice Geral

INTRODUÇÃO	1
TITLE PAGE:.....	2
MAIN TEXT:.....	3
COVER LETTER	15
DISCLOSURE OF POTENTIAL CONFLICTS AND INTERESTS.....	16
ANEXOS	28
COMPROVANTE DE SUBMISSÃO	41
RELATÓRIO DO COMITÊ DE ÉTICA	42

Índice de Tabelas

<u>TABLE 1</u>	10
<u>TABLE 2</u>	11
<u>TABLE 3</u>	12

Índice de Figuras

<u>FIGURE 1</u>	13
<u>FIGURE 2</u>	14

Lista de Abreviações

2D	Bidimensional
3D	Tridimensional
Cl III	Classe III de Angle
DICOM	Digital Imaging and Communications in Medicine
FOV	Field of View
HV	Horizontal verdadeira
PHV	Plano Horizontal Verdadeiro
PNC	Posição Natural da Cabeça
SA	Síndrome de Apert
TCFC	Tomografia Computadorizada de Feixe Cônico
Voxel	Volume Element (Elemento de Volume)
VV	Vertical Verdadeira

Introdução

As craniossinostoses sindrômicas são raras e são caracterizadas pela fusão das suturas cranianas em pacientes sindrômicos e sua prevalência é de 1:100.000 nascidos vivos. Causam restrição no crescimento do crânio e da base do crânio associados à hipoplasia do terço médio da face e dimorfismos¹.

A Síndrome de Apert foi descrita por Eugene Charles Apert em 1906 e o fenótipo dessa Síndrome inclui sinostoses bilaterais coronais da sutura, fontanela anterior ampla, hipoplasia da maxila, sindactilia de mãos e pés, perda de audição, hiperidrose, acne e anomalias da coluna vertebral. Os genes mais frequentemente mutados são os FGFRs, gerando manifestações clínicas conhecidas como síndrome de Apert, Crouzon e Pfeiffer^{2 3}. O padrão de herança autossômica dominante é bem documentado, apesar da reduzida incidência familiar, relacionado ao baixo valor adaptativo desses indivíduos, predominando a ocorrência esporádica dos casos^{4 5}.

Pacientes com craniossinostoses sindrômicas manifestam hipoplasia maxilar muitas vezes tratada pelo avanço do terço médio da face⁶.

A falta de crescimento e desenvolvimento maxilar causados pela craniossinostose resulta em aglomeração, impactação, perda prematura de dentes decíduos, erupção dentária tardia e erupção ectópica. Estas características bucais são encontradas em ambas as arcadas, mas são mais graves na maxila^{7 8}. A mandíbula é indiretamente influenciada pela ausência de deslocamento primário e secundário dos ossos do complexo maxilar e da base craniana⁹.

A Orthodontics and Craniofacial Research foi o jornal de escolha para a publicação desse estudo, pois tem o objetivo de publicar artigos relacionados com a genética, biologia do desenvolvimento, sindromologia, cirurgia, fala e audição e outras disciplinas

biomédicas relacionadas à ortodontia clínica e crescimento e desenvolvimento craniofacial normal e anormal. Portanto, esse estudo se adequa aos objetivos do jornal escolhido e pode contribuir para a comunidade científica.

Morphology of the cranial base in individuals with Apert syndrome: A cross-sectional study

Aline Cassia Inocencio
DDS, MSc in Paediatric Dentistry
Universidade de Sao Paulo
Universidade Catolica Portuguesa

José Rino Neto
DDS, MSc, PhD in Orthodontics
Universidade de São Paulo

Cassio Eduardo Adami Raposo do Amaral
MDS, PHD in Plastic Surgery
SOBRAPAR Hospital

Fausto Medeiros Mendes
DDS, MSc, PhD in Paediatric Dentistry
Universidade de São Paulo

Susana Silva
DDS, PHD in Orthodontics
Universidade Catolica Portuguesa

Ana Lúdia Ciamponi
DDS, MSc, PhD in Paediatric Dentistry
Universidade de São Paulo

Título:

Morphology of the cranial base in individuals with Apert syndrome: A cross-sectional study

Introduction

Syndromic craniosynostosis is rare and is characterised by the premature fusion of the cranial sutures in syndromic patients; its prevalence is 1:100,000 live births. It causes restriction in the growth of the skull and the base of the skull, associated with the hypoplasia of the middle third of the face and dimorphisms ^{1 2}.

Apert syndrome (AS) (OMIM # 101200) was initially described by Èugene Charles Apert in 1906 and also known as acrocephalosyndactyly. It is characterised by a phenotype that includes bilateral suture synostosis, broad anterior fontanelle, maxillary hypoplasia, complex symmetric syndactyly of the hands and feet, hearing loss, hyperhidrosis, acne and spinal anomalies. The most frequently mutated genes are FGFRs, generating clinical manifestations known as Apert, Crouzon and Pfeiffer syndrome ^{3 4 5}.

The autosomal dominant inheritance pattern is well documented, despite its low family incidence, related to the low adaptive value of these individuals, with the sporadic occurrence of cases predominating. Patients with syndromic craniosynostosis show maxillary hypoplasia, which is often treated by advancing the middle third of the face. The benefits of facial advancement through osteogenesis, or through distraction, have been studied thoroughly, but complications of infectious origin related are reported, and those responsible for such patients should be aware of the risk involved in the procedure ⁶.

The dysmorphology of the maxillary growth and development caused by craniosynostosis results in agglomeration, impaction, premature loss of deciduous teeth, late eruption of the teeth and ectopic eruption. These buccal characteristics are found in both arches, but are more severe in the maxilla ^{7 8}. The mandible is indirectly influenced by the absence of primary and secondary displacement of the bones of the maxillary complex and the cranial base. The cranial base has a great influence on the face and occlusion, since its inclination can modify the position of the maxilla and mandible,

favouring certain types of malocclusion and influencing the pattern of the facial skeleton⁹
10.

The aim of this study was to evaluate the length, width and rotation of the skull base in order to verify whether these influence the disposition of skeletal structures.

Material and Methods

This cross-sectional study was approved by the Local Ethics Committee (No. 1.366.060). Participants were included in the research after the signing of the Informed Consent Form.

The criteria for the inclusion of patients were as follows: individuals diagnosed with AS; ages between 10 and 21, did not experience any type of surgery involving advancement of the middle third of the face (monobloc advancement or bone stretching with distractors); did not use orthodontic and orthopaedic appliances prior to the study. From a total of 53 patients with AS attending the SOBRAPAR hospital, third-three were younger or older than 10-21 years old, seven had already undergone orthognatic surgery and two did not consent to participate in the study. Therefore, a total of eleven (11) adolescents and young adults with AS composed de study group (AS group).

After selection of the syndromic population, eleven healthy teenagers and young adults, paired by gender and age with AS group, were selected to compose de control group. The criteria for the inclusion of patients in this group were the following: Class I occlusion for both canines and molars; without the absence of permanent teeth; good relation between bone bases, without facial asymmetry; the presence of a lip seal and balanced facial profile, following photographic and clinical evaluation; matched in gender and age to the individuals in AS group; consented to participate in the study, by means of the signing of the Informed Consent Term.

The patients were submitted to the cone beam 3-D dental imaging system (i-Cat® - Imaging Sciences Int. USA) in a FOV 23 cm x 17 cm of 360 °, 600 image bundles, 120 kVp; 5 mA in 26 seconds, with extended height protocol. The data were saved in DICOM (Digital Imaging and Communications in Medicine) format with a voxel size of 0.25 mm. Before the tomography was performed, the patient was dressed with a plumbing apron. The patient's head was positioned and stabilised at the forehead with the aid of a Velcro strip and the patient was instructed to stand still, with lips relaxed and to swallow.

Following this, we began the extended height exam protocol. In order to evaluate the images in the software, it was necessary to import the files of the images of the Cone Been into a DICOM extension. Once the data were imported, the three-dimensional image of the patient's head was oriented in the virtual space, in order to obtain the X-ray images, as with the cephalostat. The advantage of positioning the head virtually lies in the fact that we can visualise the three planes of space in order to avoid any kind of rotation (Figure 1). In this research, the images were oriented in the natural head position to generate lateral cephalograms and facilitate both linear and angular measurements (Figure 2). This position uses the visual axis as an external reference for positioning, and it has been reported in the literature as being more suitable for orthodontic diagnosis and planning (9).

The cephalometric measures described in Table 1 were performed in an independent work station (Samsung, South Korea). Dolphin 3-D ® software (version 11.96, Dolphin Imaging and Management Solutions, Chatsworth, CA - USA) was used. The examiner was trained and calibrated by a second experienced examiner to analyse and measure computed tomography available via Dolphin software. Tomographic measurements were performed twice, with a two-week interval.

Intra-reliability was tested by a single examiner. The intraclass correlation coefficient was calculated to evaluate the level of agreement between the measurements in these two different moments. Cephalometric measurements were analysed for normality via the Shapiro-Wilk test and for the homoscedasticity of the sample via the Levene test for homoscedasticity of the sample. The measurements showed adhesion to the normality curve, and homogeneity of variances were submitted to the comparisons by the T Student-test.

Results

Initially, the intraclass correlation coefficient was verified by the two measurements performed at two different moments (Table 2), which presented values very close to 1, all of them being above 0.9, and low confidence intervals for all measures.

In Table 3, the values N.S.Ba, Fcrant ant dir- Fcrant ante esq, F crant med dir - Fcrant med esq, S-N / width of the anterior cranial fossa, S-Ba / cranial fossa width and

the mean show significant differences when compared to the control group. The N.S.Ba angle presented smaller values when compared to the control group. Regarding the other values related to the shape of the skull base, the values are higher for the AS group compared to control group.

Discussion

This study was carried out with the purpose of comparing the morphology of the cranial base of individuals with Apert syndrome with non-syndromic individuals with balanced faces. The morphology of the skull base of individuals with Apert syndrome is different to that of the normal population, but it has been shown that variations in skull morphology do not affect the accuracy of cephalometrics ¹¹.

This study was performed with concomitant computed tomography (CT) and its indication is excellent for evaluating changes in the cranial base that are difficult to assess via conventional radiographs, but are clearly observed in three-dimensional examinations on patients with complex craniomaxillofacial deformities ⁹.

When evaluating the cranial base, we intended to evaluate its angulation, length and width and to determine whether these measures have an influence on the disposition of skeletal structures ¹¹.

There was a significant difference for the angle of the cranial base (N.S.Ba) between the groups ($p = 0.0062$), for the age of studied patients. Even though Lu et al. ¹² ¹³ observed normal cranial base angle for young children (0 to 6 years of age), they described a CT for a 24-year-old patient with a widened cranial base angle in the sagittal plane, suggesting a potentially flatter cranial base. The prematurely fused spheno-occipital synchondrosis seems to influence such angulation. Sanggarnjanavanich ¹⁴, Gkantidis ¹⁵ and Andria ¹⁶ agree that the reduction of the cranial base angulation is a factor related to mandibular prognathism. The measurements of the anterior cranial base length (N-S) and total length of the cranial base (N-Ba) showed that the AS group presented smaller values compared to control group, but without significant differences ($p = 0.16$ and $p = 0.18$) respectively. Cohen ¹⁷ and Kreiborg ¹⁸ state that 15% of individuals with Apert or Crouzon syndrome have lowest skull base length when compared to the normal population. The shorter length of the skull base is probably caused by decreased growth of the spheno-occipital synchondroses and the sphenofrontal suture ¹⁹. The base of the

short skull may influence the most anterior position of the condyle, thus establishing a CI III occlusion ⁸.

The width of the anterior cranial fossa presented a significant difference between groups ($p < 0.0001$), being wider in individuals with AS. This value is in agreement with the literature, which suggests that in individuals with CI III occlusion, the anterior fossa is wider than normal ¹⁹. According to Lu et al ¹³ the widened anterior cranial fossa is the earliest and the most remarkable deformity in AS.

The proportion of the length with width of the anterior cranial fossa was different between groups ($p = 0.042$). Reports in the literature state that patients with CI III occlusion have an increase in width and height than length ²⁰. The cranial fossa length and width ratio indicated a significant difference ($p = 0.0087$) and confirmed the predominance of greater skull width than skull length in patients with AS ^{19 21 22}.

However, the angle of flexion of the base of the reduced skull (N-S-Ba) indicates a more vertical position, which favours the projection of the mandible. The length of the skull base, although showing no significant difference, showed lower values than in control group. The width of the base of the skull is greater than its length; that is, the morphology of the base of the skull is altered in patients with AS.

Conclusion

The morphology of the skull base is altered due to a more vertical rotation that changes the position of the maxilla which has a strong influence on occlusion. The skull of adolescents and young adults with Apert syndrome is wider and shorter if compared to non-syndromic individuals.

References

1. Wang JC, Nagy L, Demke JC. Syndromic Craniosynostosis. *Facial Plast Surg Clin North Am.* 2016;24(4):531-543.
2. Cohen MM, Kreiborg S, Lammer EJ, et al. Birth prevalence study of the Apert syndrome. *Am J Med Genet.* 1992;42(5):655-659.
3. Park WJ, Theda C, Maestri NE, et al. Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. *Am J Hum Genet.* 1995;57(2):321-328.
4. Burke E, Dupuy L, Wall C, Barik S. Role of cellular actin in the gene expression and morphogenesis of human respiratory syncytial virus. *Virology.* 1998;252(1):137-148.
5. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. *Genes Dev.* 2002;16(12):1446-1465.
6. Goldstein JA, Paliga JT, Taylor JA, Bartlett SP. Complications in 54 frontofacial distraction procedures in patients with syndromic craniosynostosis. *J Craniofac Surg.* 2015;26(1):124-128.
7. Cohen MM, Kreiborg S. A clinical study of the craniofacial features in Apert syndrome. *Int J Oral Maxillofac Surg.* 1996;25(1):45-53.
8. Reitsma JH, Ongkosuwito EM, Buschang PH, Prahl-Andersen B. Facial growth in patients with apert and crouzon syndromes compared to normal children. *Cleft Palate Craniofac J.* 2012;49(2):185-193.
9. Park SH, Yu HS, Kim KD, Lee KJ, Baik HS. A proposal for a new analysis of craniofacial morphology by 3-dimensional computed tomography. *Am J Orthod Dentofac Orthop.* 2006;129(5):623-634.
10. Wah PL, Cooke MS, Hägg U. Comparative cephalometric errors for orthodontic and surgical patients. *Int J Adult Orthodon Orthognath Surg.* 1995;10(2):119-126.
11. Dhopatkar A, Bhatia S, Rock P. An Investigation into the Relationship between the Cranial Base Angle and Malocclusion. *Angle Orthod.* 2002;72(5):456-463.
12. Lu X, Forte AJ, Wilson A, et al. Cranial Fossa Volume in Differing Subtypes of Apert Syndrome. *J Craniofac Surg.* 2019;30(8):2345-2349.
13. Lu X, Forte AJ, Wilson A, et al. Cranial Fossa Volume and Morphology Development in Apert Syndrome. *Plast Reconstr Surg.* 2020;145(4):790-802.

14. Sanggarnjanavanich S, Sekiya T, Nomura Y, Nakayama T, Hanada N, Nakamura Y. Cranial-base morphology in adults with skeletal Class III malocclusion. *Am J Orthod Dentofac Orthop*. 2014;146(1):82-91.
15. Gkantidis N, Halazonetis DJ. Morphological integration between the cranial base and the face in children and adults. *J Anat*. 2011(4):426-438.
16. Andria LM, Leite LP, Prevatte TM, King LB. Correlation of the cranial base angle and its components with other dental/skeletal variables and treatment time. *Angle Orthod*. 2004;74(3):361-366.
17. Cohen MM, Kreiborg S. Cranial size and configuration in the Apert syndrome. *J Craniofac Genet Dev Biol*. 1994;14(3):153-162.
18. Kreiborg S, Cohen MM. Is craniofacial morphology in Apert and Crouzon syndromes the same? *Acta Odontol Scand*. 1998;56(6):339-341.
19. Kreiborg S, Aduss H, Cohen MM. Cephalometric study of the Apert syndrome in adolescence and adulthood. *J Craniofac Genet Dev Biol*. 1999;19(1):1-11.
20. Ko EW, Chen PK, Tai IC, Huang CS. Fronto-facial monobloc distraction in syndromic craniosynostosis. Three-dimensional evaluation of treatment outcome and facial growth. *Int J Oral Maxillofac Surg*. 2012;41(1):20-27.
21. Coeugnet E, Dhellemmes P, Vinchon M, Wolber A, Pellerin P. Midfacial distraction without osteotomy using a transfacial pin and external devices. *J Craniofac Surg*. 2012;23(1):184-189.
22. Mitsukawa N, Satoh K, Hayashi T, Morishita T, Hosaka Y. Atypical Apert syndrome: sequential and segmental distraction osteogenesis of the skull, midface, and mandible. *Scand J Plast Reconstr Surg Hand Surg*. 2009;43(2):109-112.

Table 1

Table 1: Cephalometric measures of the cranial base

Variable	Measure
Angle N.S.Ba	Angle of Cranial Base
N-S	Anterior cranial base length
N-Ba	Total cranial base length
Fcran ant.right - Fcran ant.left	Width of the anterior fossa
Fcran mid.right – Fcran mid.left	Width of the middle cranial fossa
N-S / anterior cranial fossa width	Proportion of the anterior cranial length with width of the anterior cranial fossa
N-Ba / middle cranial fossa width	Proportion of the total cranial length with width of the middle cranial fossa

Table 2

Table 2: Intraclass correlation coefficient

Variable	Intraclass Correlation	CI (95%)	
		Minimum	Maximum
N.S.Ba	0.97	0.94	0.98
N-S	0.96	0.90	0.98
N-Ba	0.96	0.90	0.98
Fcran ant.right- Fcran ant.left	0.99	0.98	1.00
Fcran mid.right - Fcran mid.left	0.99	0.97	0.99
N-S / width of the anterior fossa	0.98	0.96	0.99
N-Ba / width of the middle cranial fossa	0.98	0.95	0.99

Table 3

Table 3: Comparison of angular and linear measurements for AS and control groups

Variable	Groups						
	AS group			Control group			Value P
	Media	DP	N	Media	DP	N	
N.S.Ba	120.70	10.975	11	131.04	3.423	11	0.0062*
N-S	62.08	6.693	11	66.47	5.584	11	0.1632
N-Ba	76.78	12.213	11	85.39	16.389	11	0.1840
Fcran ant.right- Fcran ant.left	158.28	12.19	11	118.47	20.308	11	< 0.0001*
Fcran mid.right - Fcran mid.left	162.23	12.528	11	125.93	20.901	11	0.0001*
N-S / width of the anterior fossa	68.75	7.550	11	60.86	10.882	11	0.0420*
N-Ba / width of the middle cranial fossa	151.54	5.252	11	120.44	1.822	11	0.0087*

*p<0,05

Figure 1



Figure 1- Representation of measurements of the width of the skull

- 1-Fcran ant.right- Fcran ant.left
- 2- Fcran mid.right - Fcran mid.left

Figure 2




Figure 2- Representation of cephalometric measurements of cranial base

- 1- S.N.Ba
- 2- N-S
- 3- N-Ba

Cover Letter

Dear Editor,

We would like to submit the article entitled 'Morphology of the Skull Base in Individuals with Apert Syndrome'. This is a cross-sectional study carried out by the authors Aline Cassia Inocencio, José Rino Neto, Cassio Eduardo Raposo do Amaral, Fausto Mendes, Susana Silva and Ana Lidia Ciamponi.

The treatment protocol for this rare syndrome (1/100,000 live births) involves multidisciplinary therapy based mainly on surgical interventions on the skullcap, however the skull base is the most affected structure in these individuals.

We performed a study with cephalometric measures to determine if there was a difference in the morphology of the skull base compared with non-syndromic individuals. Our findings demonstrated that there is a difference in the morphology of the skull base of these patients and that they can influence future treatments, both surgical and orthodontic.

We declare that the present work is original and has not been published or forwarded for publication in any other periodical or scientific journal. In addition, there is no conflict of interest and there was no external funding for this study to be carried out.

Thank you for considering our manuscript for publication in Orthodontics and Craniofacial Research.

Best regards,

Aline Cássia Inocência
Correspondence Author
Email: odontologialine@gmail.com

Disclosure of Potential Conflicts and Interests



ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization.

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations.

Non-financial Support: Sample includes drugs/equipment supplied by the entity; travel paid by the entity; writing assistance; administrative support, etc.

Other: Anything not covered under the previous three boxes.

Pending: The patent has been filed but not issued.

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether earning royalties or not.

Royalties: Funds are coming in to you or your institution due to your patent.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Inocencio has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/copyright/feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party—that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization.

Personal Fee: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations.

Non-financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes.

Pending: The patent has been filed but not issued.

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether earning royalties or not.

Royalties: Funds are coming in to you or your institution due to your patent.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ciampini has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization.

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations.

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three bases.

Pending: The patent has been filed but not issued.

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether earning royalties or not.

Royalties: Funds are coming in to you or your institution due to your patent.

**ICMJE Form for Disclosure of Potential Conflicts of Interest****Section 5. Relationships not covered above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Generate Disclosure Statement

Dr. Silva has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party—that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization.

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lecturing, speakers bureaus, expert testimony, employment, or other affiliations.

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes.

Pending: The patent has been filed but not issued.

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether earning royalties or not.

Royalties: Funds are coming in to you or your institution due to your patent.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. do Amaral has nothing to disclose.

Evaluation and Feedback

Please visit <https://www.icmje.org/online/feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization.

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations.

Non-financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes.

Pending: The patent has been filed but not issued.

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether earning royalties or not.

Royalties: Funds are coming in to you or your institution due to your patent.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rino Neto has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/online-feedback> to provide feedback on your experience with completing this form.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization.

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations.

Non-financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes.

Pending: The patent has been filed but not issued.

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether earning royalties or not.

Royalties: Funds are coming in to you or your institution due to your patent.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- ☒ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Mendes has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/topic/in/feedback> to provide feedback on your experience with completing this form.

Anexos

Author Guidelines

Sections

- [1. Submission](#)
- [2. Aims and Scope](#)
- [3. Manuscript Categories and Requirements](#)
- [4. Preparing the Submission](#)
- [5. Editorial Policies and Ethical Considerations](#)
- [6. Author Licensing](#)
- [7. Publication Process After Acceptance](#)
- [8. Post Publication](#)
- [9. Editorial Office Contact Details](#)

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at [**https://mc.manuscriptcentral.com/ocr**](https://mc.manuscriptcentral.com/ocr)

[Click here](#) for more details on how to use ScholarOne.

Data protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at [**https://authorservices.wiley.com/statements/data-protection-policy.html**](https://authorservices.wiley.com/statements/data-protection-policy.html).

Preprint policy

[Please find the Wiley preprint policy here.](#)

This journal does not accept articles previously published on preprint servers.

For help with submissions, please contact: [**OCRedoffice@wiley.com**](mailto:OCRedoffice@wiley.com)

2. AIMS AND SCOPE

Orthodontics & Craniofacial Research is published to serve its readers as an international forum for the presentation and critical discussion of issues pertinent to the advancement of the specialty of orthodontics and the evidence-based knowledge of craniofacial growth and development. This forum is based on scientifically supported information, but also includes minority and conflicting opinions.

The objective of *Orthodontics & Craniofacial Research* is to facilitate effective communication between the research community and practicing clinicians. Original Papers of high scientific quality that report the findings of clinical trials, clinical epidemiology, and novel therapeutic or diagnostic approaches are appropriate submissions. Similarly, we welcome papers in genetics, developmental biology, syndromology, surgery, speech and hearing, and other biomedical disciplines related to clinical orthodontics and normal and abnormal craniofacial growth and development. In addition to original and basic research, the journal publishes Critical Commentaries, Short Communications, Reviews, Letters, and Meeting Reports.

Orthodontics & Craniofacial Research is published quarterly. The review of submitted papers will be coordinated by the editor and members of the editorial board. It is policy to review manuscripts within 4 to 6 weeks of receipt and to publish within 3 to 6 months of acceptance.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

i. Original Research Articles

Original Research Articles of high scientific quality that report the findings of clinical trials, clinical epidemiology, and novel therapeutic or diagnostic approaches are appropriate submissions. Similarly, we welcome papers in genetics, developmental biology, syndromology, surgery, speech and hearing, and other biomedical disciplines related to clinical orthodontics and normal and abnormal craniofacial growth and development. Only manuscripts reporting the results of original clinical or clinically relevant investigations are suitable for publication.

Word limit: 4,000 words maximum, excluding Title page, Abstract, References figure legends and Acknowledgment; including Introduction, Materials and Methods, Results, Discussion, Conclusions.

Abstract: 250 words maximum; must be structured, under the sub-headings: Objective(s), Materials and Methods (include design, setting, subject and main outcome measures as appropriate), Results, Conclusion.

References: Maximum of 40 references.

Figures/Tables: Total of no more than 6 figures and/or tables.

Main text structure: The main text should be structured under the headings Introduction, Material and Methods, Results, Discussion, Conclusions.

ii. Short Communications

Priority will be given to communications relating to primary research data. This section permits time-sensitive material to be published within 6 months of submission.

Word limit: 2,000 words maximum, excluding references.

Abstract: 150 words maximum.

References: Maximum 20 references.

Figures/Tables: Total of no more than 3 figures and/or tables.

Main text structure: The main text should be structured under the headings Introduction, Material and Methods, Results, Discussion, Conclusions.

iii. Reviews

Systematic reviews and meta-analyses are preferred above narrative reviews.

Word limit: 5,000 words maximum.

Abstract: 250 words maximum.

References: No limit.

Figures/Tables: Total of no more than 6 figures and/or tables.

Main text structure: Headings may be used as appropriate.

iv. Letters to the Editor

Letter to the Editor are encouraged to stimulate scientific discussions on recently published papers. The Editor will refer them to the authors. The readers' comments and authors' replies may subsequently be published together.

Word limit: 1,500 words maximum, excluding references.

References: Maximum 5 references.

Tables and Figures: Total of no more than 1 figure or table.

v. Meeting Reports

Proceedings of significant meetings may also be published at the discretion of the Editor-in-Chief.

Case Reports are no longer accepted.

4. PREPARING THE SUBMISSION

Cover Letters

Cover letters are not mandatory; however, they may be supplied at the author's discretion.

Parts of the Manuscript

The manuscript should be submitted in separate files: title page; main text file; figures.

Title Page

The title page should contain:

- i. A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's [best practice SEO tips](#));
- ii. A short running title of less than 40 characters;
- iii. The full names of the authors;
- iv. The author's institutional affiliations where the work was conducted, with a footnote for the author's present address if different from where the work was conducted;
- v. Acknowledgments.

Authorship

Please refer to the journal's authorship policy the [Editorial Policies and Ethical Considerations section](#) for details on eligibility for author listing.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the section 'Conflict of Interest' in the [Editorial Policies and Ethical Considerations section](#) below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Main Text File

As papers are double-blind peer reviewed, the main text file should not include any information that might identify the authors.

The main text file should be presented in the following order:

- i. Title (should not contain abbreviations), abstract, and key words;
- ii. Main text;
- iii. References;
- iv. Tables (each table complete with title and footnotes);
- v. Figure legends;
- vi. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

Abstract

Abstracts and keywords are required for some manuscript types. For details on manuscript types that require abstracts, please refer to the 'Manuscript Types and Criteria' section.

Keywords

Please provide 3-5 keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh.

Main Text

- As papers are double-blind peer reviewed, the main text file should not include any information that might identify the authors.

- **Introduction:** Should contain the hypothesis, the rationale of the study. References should only develop the argument. This section is not an exhaustive literature review. Aim and/or working hypothesis, if applicable, must be clearly stated in the last paragraph of the section.
- **Materials and Methods:** Should contain sufficient pertinent detail to allow duplication of the study. Use appropriate subheadings for the different sections to obtain clarity. References should be provided wherever possible. Legends to the figures may also contain summary information of methods. Statistical methods employed should be identified in this section. When submitting review manuscripts, particularly Systematic Reviews, include a section describing the methods used in locating, selecting, extracting, and synthesizing data. Summarize these methods in the abstract.
- **Results:** Should be presented clearly in logical sequence. For clarity, subheadings may be used. The Results section is not the place for interpretation of the data. Graphs or representative illustrations should be included in this section. Do not repeat in the text, data easily found in the tables or illustrations (double documentation is not acceptable). The author(s) should indicate where to place the illustrations in the text.
- **Discussion:** Do not repeat what has already been reported in the results section, or in the introduction! Results should be interpreted and discussed here in view of the previously published studies. This section is the only proper section for subjective comments.
- **Conclusions:** The last paragraph should be dedicated to the conclusions of the study. There ought to be a correspondence between the aims and hypotheses in the end of the introduction and conclusions. Conclusions in the abstract should be comparable.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. For more information about AMA reference style please consult the [AMA Manual of Style](#)

Sample references follow:

Journal *article*

1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. *J Comp Neurol* 1998;390:537-551.

Book

2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Internet

document

3. American Cancer Society. Cancer Facts & Figures 2003. <http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf> Accessed March 3, 2003

Tables

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

The main purpose of the illustrations is to clarify the results. Micrographs should be designed to reproduce without reduction. Individual photographs should be unmounted. If grouped, however, they may be lightly mounted. Line drawings should be professionally prepared. Locations of illustrations should be identified in the manuscript. An abbreviated description of methods that generated the data is an appropriate inclusion in the legend.

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

[Click here](#) for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Color Figures. Figures submitted in color may be reproduced in colour online free of charge. Please note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white. If an author would prefer to have figures printed in colour in hard copies of the journal, a fee will be charged by the Publisher.

Reproduction of Copyright Material

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author's responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley's Copyright Terms & Conditions FAQ at <http://exchanges.wiley.com/authors/faqs---copyright-terms--conditions> 301.html

Data Citation

[Please review Wiley's data citation policy here.](#)

Additional Files

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

[Click here](#) for Wiley's FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

- **Abbreviations, Symbols and Nomenclature:** In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only. Only standardized terms, which have been generally accepted, should be used. Units, Symbols and Abbreviations. 5th ed. London: The Royal Society of Medicine; 1994, will be the reference source for these. Unfamiliar abbreviations must be defined when first used. 'The two-digit system' should be used for tooth identification (see Federation Dentaire Internationale (1971) Int Dent J 1971; 21:104-6).
- **Units of measurement:** Measurements should be given in SI or SI-derived units. Visit the [Bureau International des Poids et Mesures \(BIPM\) website](#) for more information about SI units.
- **Scientific Names:** All Latin or foreign words must be italicized throughout the text.
- **Decimal points:** Please use full stop as decimal point, not comma.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available [here](#). In particular, authors may benefit from referring to Wiley's best practice tips on [Writing for Search Engine Optimization](#).

Article Preparation Support: [Wiley Editing Services](#) offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for [Preparing Your Article](#) for general guidance about writing and preparing your manuscript.

Guidelines for Cover Submissions: If you would like to send suggestions for artwork related to your manuscript to be considered to appear on the cover of the journal, please follow these [general guidelines](#).

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Manuscripts are double-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

Appropriate papers are sent to at least two independent referees for evaluation. Authors are encouraged to suggest reviewers of international standing. Referees advise on the originality and scientific merit of the paper; the Editor in Chief and editorial board, decide on publication. The Editor-in-Chief's decision is final.

Wiley's policy on the confidentiality of the review process is [available here](#).

Guidelines on Publishing and Research Ethics in Journal Articles

[Please review Wiley's policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines here.](#)

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: 'These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345'. Addresses are as follows:

- DNA Data Bank of Japan (DDBJ): www.ddbj.nig.ac.jp
- EMBL Nucleotide Archive: ebi.ac.uk/ena
- GenBank: www.ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories:

- Protein Information Resource (PIR): pir.georgetown.edu
- SWISS-PROT: expasy.ch/sprot/sprot-top

Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). **Please note that the data in databanks must be released, at the latest, upon publication of the article.** We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

- Organic and organometallic compounds: Crystallographic data should not be sent as Supporting Information, but should be deposited with the *Cambridge Crystallographic Data Centre* (CCDC) at ccdc.cam.ac.uk/services/structure%5Fdeposit.
- Inorganic compounds: *Fachinformationszentrum Karlsruhe* (FIZ; fiz-karlsruhe.de).
- Proteins and nucleic acids: *Protein Data Bank* (rcsb.org/pdb).
- NMR spectroscopy data: *BioMagResBank* (bmrb.wisc.edu).

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

The above policies are in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals produced by the International Committee of Medical Journal Editors (<http://www.icmje.org/>). It is the responsibility of the corresponding author to have all authors of a manuscript fill out a conflict of interest disclosure form, and to upload all forms together with the manuscript on submission. The disclosure statement should be included under Acknowledgements. Please find the form below:

Conflict of Interest Disclosure Form

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: <https://www.crossref.org/services/funder-registry/>

Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; and
2. Been involved in drafting the manuscript or revising it critically for important intellectual content; and
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

Data Sharing and Data Accessibility

[Please review Wiley’s policy here](#). This journal encourages and peer review data sharing.

The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

All accepted manuscripts may elect to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. [Sample statements are available here](#). If published, statements will be placed in the heading of your manuscript.

Publication Ethics

This journal is a member of the [Committee on Publication Ethics \(COPE\)](#). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors [here](#). Wiley’s Publication Ethics Guidelines can be found [here](#).

ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. [Find more information here](#).

6. AUTHOR LICENSING

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal's standard copyright agreement, or [OnlineOpen](#) under the terms of a Creative Commons License.

General information regarding licensing and copyright is available [here](#). To review the Creative Commons License options offered under OnlineOpen, please [click here](#). (Note that certain funders mandate that a particular type of CC license has to be used; to check this please click [here](#).)

Self-Archiving definitions and policies. Note that the journal's standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please [click here](#) for more detailed information about self-archiving definitions and policies.

Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list of Article Publication Charges for Wiley journals is available [here](#).

Funder Open Access: Please click [here](#) for more information on Wiley's compliance with specific Funder Open Access Policies.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted article received in production

When an accepted article is received by Wiley's production team, the corresponding author will receive an email asking them to login or register with [Wiley Author Services](#). The author will be asked to sign a publication license at this point.

Accepted Articles

The journal offers Wiley's Accepted Articles service for all manuscripts. This service ensures that accepted 'in press' manuscripts are published online shortly after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance and appear in PDF format only. They are given a Digital Object Identifier (DOI), which allows them to be cited and tracked and are indexed by PubMed. After the final version article is published (the article of record), the DOI remains valid and can still be used to cite and access the article.

Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is accurate for indexing. Subsequently, the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will update automatically.

Proofs

Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of first proof.

Publication Charges

Colour figures. Colour figures may be published online free of charge; however, the journal charges for publishing figures in colour in print. If the author supplies colour figures at Early View publication, they will be invited to complete a colour charge agreement in RightsLink for Author Services. The author will have the option of paying immediately with a credit or debit card, or they can request an invoice. If the author chooses not to purchase color printing, the figures will be converted to black and white for the print issue of the journal.

Early View

The journal offers rapid speed to publication via Wiley's Early View service. [Early View](#) (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.

8. POST PUBLICATION

Access and sharing

When the article is published online:

- The author receives an email alert (if requested).
- The link to the published article can be shared through social media.
- The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
- The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

Promoting the Article

To find out how to best promote an article, [click here](#).

Article Promotion Support

[Wiley Editing Services](#) offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with [Kudos](#) and [Altmetric](#).

9. EDITORIAL OFFICE CONTACT DETAILS


For queries about submissions, please contact OCRedoffice@wiley.com

Author Guidelines Updated 22 November 2019

Comprovante de Submissão

ScholarOne Manuscripts™		ALINE INOCENCIO	Instructions & Forms	Help	Log Out
-------------------------	--	-----------------	----------------------	------	---------

Orthodontics & Craniofacial Research



[Home](#) / [Author](#) / [Review](#)

Author Dashboard / Submission Confirmation

Submission Confirmation

Print

Thank you for your submission

Submitted to	Orthodontics and Craniofacial Research
Manuscript ID	OCR-2020-06-190-ORI
Title	Morphology of the cranial base in individuals with Apert syndrome: A cross-sectional study
Authors	INOCENCIO, ALINE Rino Neto, José do Amaral , Cassio Mendes, Fausto M. Silva, Susana Clamponil , Ana
Date Submitted	04-Jun-2020

Author Dashboard >

Relatório do Comitê de Ética

Comitê de Ética
UNIVERSIDADE DE SÃO PAULO FACULDADE DE ODONTOLOGIA
COMITÊ DE ÉTICA EM PESQUISA

Parecer de Aprovação

Protocolo 1.366.060

CAAE: 50825415.8.0000.0075

Com base em parecer de relator, o Comitê de Ética em pesquisa APROVOU o protocolo de pesquisa Crescimento Craniofacial e padrão de alinhamento dentário em pacientes com Síndrome de Apert de responsabilidade da Pesquisadora Aline Cássia Inocêncio sob orientação da Professora Ana Lúcia Ciampi.

Tendo em vista a legislação vigente, devem ser encaminhados a este Comitê relatórios anuais referentes ao andamento da pesquisa e ao término cópia do trabalho em "cd". Qualquer emenda do projeto original deve ser apresentada a este CEP para apreciação, de forma clara e sucinta, identificando a parte do protocolo a ser modificada e suas justificativas.

São Paulo 30 de maio de 2016

Profa.Dra. Maria Gabriela Haye Blazevic
Coordenadora do CEP-FOUSP